Patents Assigned to Medical College of Georgia
-
Publication number: 20090196859Abstract: The present invention provides a cell culture enriched for sphingolipid enhances neural stem cells (SENSe), particularly oligodendrocyte precursor cells (ODPCs), that do not form teratomas after transplanted in vivo. Methods for producing and use of the invention ODPCs or the cell culture enriched with these ODPCs for stem cell therapy are also provided. The invention method comprises culturing a stem cell culture with a cell culture medium comprising a ceramide compound and a S1P receptor agonist in sequence, overlapping intervals or concurrent manners. The present invention further provides a cellular or gene therapy using a composition comprising a ceramide compound in conjunction with a S1P1 agonist to proliferate or differentiate endogeneous neural stem cells to ODPCs and further to oligodendrocytes.Type: ApplicationFiled: February 4, 2009Publication date: August 6, 2009Applicant: Medical College of Georgia Research InstituteInventor: Erhard Bieberich
-
Publication number: 20090190817Abstract: A system and method for minimizing, if not completely eliminating, the systematic bias present in an MR system used for DTI is disclosed. A test object or “phantom” of the present invention is scanned with a desired DTI protocol. The eigenvalues measured with the phantom are compared to the actual values that should have been measured, and a parametric map that links measured eigenvalues to actual eigenvalues is calculated, which is applicable to the desired protocol. Future eigenvalue measurements using this protocol can be recalibrated to actual eigenvalues using this map.Type: ApplicationFiled: January 15, 2009Publication date: July 30, 2009Applicant: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC.Inventors: Nathan E. Yanasak, Tom C. Hu
-
Publication number: 20090190816Abstract: A method for scaling MR signal intensity after noise has been removed is disclosed. Because the signal in a DTI series varies with the apparent diffusivity in the direction of an applied gradient, one can multiply image data collected under actual clinical conditions with a spatially-dependent scaling function to synthesize different spatial diffusion distributions, after removal of noise. Recombination of the data with the removed noise preserves the bias in the system.Type: ApplicationFiled: January 15, 2009Publication date: July 30, 2009Applicant: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INC.Inventors: Nathan E. Yanasak, Tom C. Hu
-
Patent number: 7550617Abstract: Derivative compounds of 11-nonyloxy-undec-8(Z)-eonic acid that mimic epoxide metabolites are provided. Also provided are compositions comprising a therapeutically effective amount of the derivative compounds. The present invention further provides methods for the use of such compositions for the treatment of renal or cardiovascular disease and/or related conditions.Type: GrantFiled: October 2, 2007Date of Patent: June 23, 2009Assignees: Medical College of Georgia Research Institute, Board of Regents, The University of Texas SystemInventors: John D. Imig, John R. Falck
-
Publication number: 20090123388Abstract: Prodrugs made up of biologically-active short-chain fatty acids or derivatives thereof conjugated to neutral or cationic amino acids capable of intracellular transport by ATB0,+ are provided. The short-chain fatty acid or derivative thereof can be attached to the amino acid through a hydroxyl group of the amino acid to form a fatty acid ester of the amino acid, or it can be attached through the amino group of the amino acid to form a fatty-acid amide of the amino acid. Serine butyrate (O-butyryl serine) is a preferred prodrug. These prodrugs are useful for treatment of colon cancer, inflammatory bowel disease, ulcerative colitis, Crohn's disease, lung cancer, cervical cancer, and cancers resulting from metastases from primary colon cancer sites. Methods of delivering biologically-active short-chain fatty acids or derivatives thereof to cells in need of these molecules and methods of treating diseases using the prodrugs of this invention are also provided.Type: ApplicationFiled: January 17, 2006Publication date: May 14, 2009Applicant: Medical College of Georgia Research InstituteInventors: Vadivel Ganapathy, Puttur D. Prasad, Robert G. Martindale
-
Publication number: 20090123420Abstract: The present invention provides improved treatment methods by the administration of the non-physiologic D-isomer of an IDO inhibitor.Type: ApplicationFiled: July 18, 2008Publication date: May 14, 2009Applicant: Medical College of Georgia Research Institute, IncInventors: David Munn, Andrew Mellor
-
Publication number: 20090081155Abstract: The present invention provides improved treatment methods by the administration of both an inhibitor of indoleamine-2,3-dioxygenase in addition to the administration of an additional therapeutic agent.Type: ApplicationFiled: July 18, 2008Publication date: March 26, 2009Applicant: Medical College of Georgia Research Institute, IncInventors: David Munn, Andrew Mellor
-
Publication number: 20090035285Abstract: The present invention provides compositions and methods for human neural cell production. More particularly, the present invention provides cellular differentiation methods employing amphiphilic lipid compounds, preferably ceramide analogs of the ?-hydroxyalkylamine type and optionally employing an essentially serum free MEDII conditioned medium for the generation of human neural cells from pluripotent human cells. The methods alternatively comprise modulating apoptosis by modifying the levels of PAR-4, with or without the presence of amphiphilic lipid compounds and optionally employing MEDII conditioned medium. The methods alternatively encompass modulating apoptosis by modulating the intracellular concentration of endogenous lipid second messengers, such as ceramide.Type: ApplicationFiled: September 22, 2008Publication date: February 5, 2009Applicants: BRESAGEN, INC., MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTEInventors: Brian G. Condie, Erhard Bieberich
-
Patent number: 7465448Abstract: The present invention provides methods and compositions to reduce immune tolerance at specific sites. In one aspect, the present invention comprises methods and compositions to reduce tumorigenicity. In an embodiment, the present invention reduces recruitment of tolerance-inducing antigen presenting cells (APCs) or their precursors to a tumor and/or tumor draining lymph node by decreasing binding of at least one tumor-associated ligand to a chemokine receptor present on the tolerance-inducing APCs or APC precursors. In an embodiment, the chemokine receptor is CCR6 and the tumor-associated ligand is mip-3?. In another aspect, the present invention comprises methods and compositions to reduce immune tolerance to a virus. In an embodiment, the virus is HIV. The present invention further provides for the development of CCR6 antibodies and antagonists as therapeutic agents to prevent or reduce immune tolerance.Type: GrantFiled: September 11, 2003Date of Patent: December 16, 2008Assignee: Medical College of Georgia Research Institute, Inc.Inventors: David H. Munn, Andrew L. Mellor
-
Patent number: 7445931Abstract: The present invention provides compositions and methods for human neural cell production. More particularly, the present invention provides cellular differentiation methods employing amphiphilic lipid compounds, preferably ceramide analogs of the ?-hydroxyalkylamine type and optionally employing an essentially serum free MEDII conditioned medium for the generation of human neural cells from pluripotent human cells. The methods alternatively comprise modulating apoptosis by modifying the levels of PAR-4, with or without the presence of amphiphilic lipid compounds and optionally employing MEDII conditioned medium. The methods alternatively encompass modulating apoptosis by modulating the intracellular concentration of endogenous lipid second messengers, such as ceramide.Type: GrantFiled: September 25, 2003Date of Patent: November 4, 2008Assignees: Bresagen, Inc., Medical College of Georgia Research InstituteInventors: Brian G. Condie, Erhard Bieberich
-
Publication number: 20080131453Abstract: The field of this invention is the development of therapeutic agents having immunogenic efficacy against Campylobacter. The present invention is directed to a method of producing monoclonal antibodies that are highly specific for epitopes of Campylobacter jejuni outer membrane proteins; to specific monoclonal antibodies made by using the epitopes; and to uses thereof. The invention is drawn further to immunogens comprising certain outer membrane proteins or portions thereof from C. jejuni.Type: ApplicationFiled: November 15, 2007Publication date: June 5, 2008Applicant: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTEInventor: Stuart A. Thompson
-
Publication number: 20080131836Abstract: An illumination device including an integrating sphere and at least one light source. The integrating sphere is hollow and houses the at least one light source in it. The light source can be manipulated between a first configuration and a second configuration. The illumination device emits a first spectrum of light when the light source is in the first configuration, and a second spectrum of light when the light source is in the second configuration.Type: ApplicationFiled: January 23, 2008Publication date: June 5, 2008Applicant: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INCInventor: Frederick A. RUEGGEBERG
-
Publication number: 20080077439Abstract: A calendar-format medication instruction sheet is produced when a pharmacy processes a patient's prescription. The sheet can bear icons or photographic images of the medications that the patient is to take, overlayed on a calendar grid to indicate the days on which the patient is to take them, and can also bear icons or photographic images indicating how the patient is to take them. The icons, photographic images, or other graphical information can be obtained from a remote server as needed.Type: ApplicationFiled: September 20, 2007Publication date: March 27, 2008Applicant: MEDICAL COLLEGE OF GEORGIA RESEARCH INSTITUTE, INCInventor: Willie K. GUION
-
Patent number: 7259180Abstract: The present invention describes linking a therapeutic agent to a compound which is known to be naturally concentrated in a tissue affected by, or that is causing, a disease, to create a prodrug for treatment of the disease. Embodiments of the present invention include a new class of carotenoid-linked drugs to treat such blinding retinal disease such as age-related macular degeneration, retinoblastoma, and diabetic macular edema. For example, the present invention comprises a method for the treatment of a disorder of the eye comprising linking a therapeutic agent to a xanthophyll carotenoid to create a prodrug, and administering a therapeutically effective amount of the prodrug to an individual in need of treatment. Provided are prodrugs for treatment of retinoblastoma, cystoid macular edema (CME), exudative age-related macular degeneration (AMD), diabetic retinopathy, diabetic macular edema, or inflammatory disorders.Type: GrantFiled: August 13, 2003Date of Patent: August 21, 2007Assignees: University of Georgia Research Foundation, Inc., Medical College of Georgia Research Institute, Inc.Inventors: Dennis Michael Marcus, Chung Kwang Chu
-
Publication number: 20070162119Abstract: A prefabricated tympanic membrane prosthesis includes a piece of collagen sheet processed with a diluted solution of formalin. The piece of collagen sheet is molded on a forming surface of a tool having a shape resembling a natural tympanic membrane of a human subject. The piece of collagen sheet is processed with a diluted solution of formalin so that the resulting tympanic membrane prosthesis retains the shape of the forming surface. The tympanic membrane prosthesis is semi-rigid, yet flexible, and is packaged in a substantially rigid container to protect it shape during shipment and storage.Type: ApplicationFiled: January 8, 2007Publication date: July 12, 2007Applicant: Medical College of Georgia Research Institute, Inc.Inventor: Alan J. Johnson
-
Patent number: 7220851Abstract: A number of cDNA clones whose products may interact with D1 receptors in vivo were identified. One of the clones, P24, was characterized further. P24 is localized in dendrites and spines of pyramidal cells in PFC. The extent of overlap between P24 expressing and D1 receptor expressing pyramidal cells appeared to be 100%. In contrast, only a limited number D1 receptor antibody labeled neurons in caudate expressed P24. P24 lowers the threshold of D1 receptor response to dopamine (DA) by an order of magnitude. Sequence similarity suggests P24 is a diverged member of the RAMP family. The P24 protein is therefore referred to as a D1 DA RAMP, calcyon. The isolated protein and nucleotide molecule encoding the protein, as well as primers for the nucleotide, are described. The protein and compounds modifying DA binding to the receptor or calcium release which is mediated by the Calcyon, are useful in research studies, drug screening, and therapeutically.Type: GrantFiled: September 9, 2002Date of Patent: May 22, 2007Assignee: Medical College of Georgia Research Institute, Inc.Inventor: Clare Bergson
-
Publication number: 20070077224Abstract: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO.Type: ApplicationFiled: November 21, 2006Publication date: April 5, 2007Applicant: Medical College of Georgia ResearchInventors: David Munn, Andrew Mellor
-
Publication number: 20070077234Abstract: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment. Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO.Type: ApplicationFiled: November 21, 2006Publication date: April 5, 2007Applicant: Medical College of Georgia ResearchInventors: David Munn, Andrew Mellor
-
Patent number: 7173119Abstract: Novel nucleic acids associated with Type 1 diabetes. Also provided are polypeptides encoded by the nucleic acids associated with T1D. The invention also provides methods for facilitating the diagnosis or pre-diagnosis of T1D through the use of such nucleic acids and polypeptides. This invention further provides compositions for the treatment of Type 1 diabetes.Type: GrantFiled: March 25, 2005Date of Patent: February 6, 2007Assignee: Medical College of Georgia Research InstituteInventors: Jin-Xiong She, Cong-Yi Wang
-
Patent number: 7160539Abstract: A mechanism of macrophage-induced T cell suppression is the selective elimination of tryptophan and/or increase in one or more tryptophan metabolites within the local macrophage microenvironment Studies demonstrate that expression of IDO can serve as a marker of suppression of T cell activation, and may play a significant role in allogeneic pregnancy and therefore other types of transplantation, and that inhibitors of IDO can be used to activate T cells and therefore enhance T cell activation when the T cells are suppressed by pregnancy, malignancy or a virus such as HIV. Inhibiting tryptophan degradation (and thereby increasing tryptophan concentration while decreasing tryptophan metabolite concentration), or supplementing tryptophan concentration, can therefore be used in addition to, or in place of, inhibitors of IDO.Type: GrantFiled: March 28, 2002Date of Patent: January 9, 2007Assignee: Medical College of GeorgiaInventors: David Munn, Andrew Mellor